“Multiple myeloma disproportionately affects people over the age of 65 and African Americans, and it leads to progressive bone destruction, severe anemia, infectious complications and kidney and heart damage from abnormal proteins produced by the malignant plasma cells. Less than half of patients with multiple myeloma live beyond 5 years.”About 12,590 deaths are expected from multiple myeloma this year in the United States, according to the American Cancer Society. The award was the first for Poseida from CIRM. The company is providing $8.6 million in co-funding.
Like all the awards today, the Poseida award was approved earlier in a closed door meeting by reviewers who do not have to publicly disclose their economic or professional conflicts of interest.
There was no board discussion today of the Poseida award nor of the third award, $4.8 million to Childrens' Hospital of Los Angeles. Its phase one trial involves testing the feasibility of using engineered T-cells to fight viruses that can kill patients with weakened immune systems. Those patients include persons undergoing chemotherapy, bone marrow or cord blood transplants.
Childrens' Hospital Los Angeles earlier had received $26.3 million from the agency.
The agency has helped to finance 16 clinical trials in 2017 alone. Whether it will continue at this pace in 2018 is expected to be discussed at its December board meeting. Some board members have indicated it would be of some benefit to slow the pace of funding to extend the life of the agency.
Here is a link to the overall staff presentation on the applications. Here are links to the summaries of the grant reviewers comments: California Institute for Biomedical Research application CLIN2
-10388, Poseida application CLIN2-10392, and Childrens' Hospital application CLIN2-10392.
More information on the Poseida clinical trial, which is now recruiting, can be found here.
More information on all the agency's clinical trials can be found on CIRM’s Clinical Dashboard.